Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab with Chemoradiotherapy for Rectal Cancer
NCT06599827Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in rectal cancer, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Pathologic Complete Response. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06599827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06599827.